Holen Sie sich die Stockscreener-App
1.86
22.82%
-0.55
Handel nachbörslich:
1.83
-0.03
-1.61%
Schlusskurs vom Vortag:
$2.41
Offen:
$1.75
24-Stunden-Volumen:
4.85M
Relative Volume:
4.85
Marktkapitalisierung:
$239.33M
Einnahmen:
$514.70M
Nettoeinkommen (Verlust:
$2.72M
KGV:
-11.71
EPS:
-0.1589
Netto-Cashflow:
$17.08M
1W Leistung:
-21.52%
1M Leistung:
-25.60%
6M Leistung:
-50.66%
1J Leistung:
-58.85%
1-Tages-Spanne:
$1.54
$1.88
1-Wochen-Bereich:
$1.54
$2.45
52-Wochen-Spanne:
$1.54
$7.0771
Organogenesis Holdings Inc Stock (ORGO) Company Profile
Firmenname
Organogenesis Holdings Inc
Sektor
Telefon
781-575-0775
Adresse
85 DAN ROAD, CANTON, MA
Compare ORGO vs TAK, HLN, TEVA, ZTS, UTHR
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ORGO
Organogenesis Holdings Inc
|
1.86 | 328.12M | 514.70M | 2.72M | 17.08M | -0.1589 |
TAK
Takeda Pharmaceutical Co Adr
|
17.45 | 55.69B | 29.91B | 1.30B | 3.49B | 0.4056 |
HLN
Haleon Plc Adr
|
10.03 | 43.77B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
35.36 | 36.19B | 17.53B | 1.58B | 444.18M | 1.3457 |
ZTS
Zoetis Inc
|
72.66 | 32.25B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
538.84 | 26.29B | 3.17B | 1.29B | 1.01B | 27.09 |
Organogenesis Holdings Inc Stock (ORGO) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-06-28 | Eingeleitet | Lake Street | Buy |
| 2024-02-07 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2023-06-15 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2023-05-24 | Hochstufung | BTIG Research | Neutral → Buy |
| 2022-11-10 | Herabstufung | BTIG Research | Buy → Neutral |
| 2022-08-10 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2020-01-10 | Eingeleitet | SVB Leerink | Outperform |
| 2019-08-26 | Fortgesetzt | Credit Suisse | Outperform |
| 2019-05-02 | Eingeleitet | Credit Suisse | Outperform |
| 2019-04-17 | Eingeleitet | Oppenheimer | Outperform |
| 2019-04-11 | Eingeleitet | SunTrust | Buy |
Alle ansehen
Organogenesis Holdings Inc Aktie (ORGO) Neueste Nachrichten
Organogenesis Holdings Inc (ORGO) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Organogenesis reports positive trial results for wound care product - Investing.com
Organogenesis Announces Published RCT Results Showing Affinity Plus Standard of Care Improves Closure Rates in Complex Venous Leg Ulcers - Quiver Quantitative
Peer-reviewed Affinity trial finds higher closure in leg wounds over 24 months - Stock Titan
ORGO|Organogenesis Holdings Inc|Price:2.390|Chg%:-0.040 - TradingKey
Organogenesis Holdings Inc (ORGO) Cash Flow - TradingKey
ORGO|Organogenesis Holdings Inc|Price:2.550|Chg%:+0.160 - TradingKey
Organogenesis Holdings Inc (ORGO) Balance Sheet - TradingKey
Organogenesis Holdings Inc (ORGO) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Organogenesis Holdings Inc - TradingKey
Organogenesis Holdings Inc (ORGO) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Organogenesis Holdings Inc (ORGO) Institutional Confidence - TradingKey
TradingKey - TradingKey
Organogenesis Holdings, Inc. Class A Revenue Breakdown – DUS:2PQ - TradingView
Organogenesis Holdings Inc. (ORGO) stock price, news, quote and history - Yahoo Finance Singapore
Organogenesis Holdings Inc (ORGO) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
ORGO INVESTOR ALERT: Hagens Berman, National Trial Attorneys, Encourages Organogenesis Holdings (ORGO) Investors with Substantial Losses to Contact Firm's Attorneys, Securities Fraud Class Action Filed - TMX Newsfile
Organogenesis Holdings Inc (ORGO) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
ORGO|Organogenesis Holdings Inc|Price:2.335|Chg%:-0.095 - TradingKey
Organogenesis Holdings (ORGO) Slides 7.8% as Stock Tests Key Support ZoneIV Expansion Alert - dars.gov.et
Pegasystems Posts Downbeat Q2 Results, Joins Adtran, Dyne Therapeutics And Other Big Stocks Moving Lower In Wednesday’s Pre-Market Session - Sahm
3 Penny Stocks With Market Caps Over $100M To Consider - simplywall.st
Organogenesis Holdings (ORGO) Slips 1.87% as Resistance Holds; Key Levels in FocusSell Signal Alerts - dars.gov.et
Organogenesis stock trades steadily as wound care margins support outlook - Ad-hoc-news.de
Organogenesis Holdings (ORGO) Surges 7.23% as Stock Finds Traction Above SupportOvernight Profile - dars.gov.et
ORGO Q1 2026 Earnings: EPS Miss by Significant Margin, Stock DeclinesQuarterly Profit Report - dars.gov.et
Organogenesis (ORGO) AGM 2026 Summary - Quartr
Organogenesis (ORGO) Proxy filing Summary - Quartr
Organogenesis (ORGO) Q1 2026 earnings summary - Quartr
Organogenesis (ORGO) Q1 2025 earnings summary - Quartr
Organogenesis Holdings Inc. to Report Second Quarter of Fiscal Year 2026 Financial Results on August 6, 2026 - The Manila Times
Organogenesis Holdings (ORGO) Q1 2026 Earnings: Substantial EPS Miss Pressures SharesEarnings Acceleration Picks - dars.gov.et
Organogenesis Holdings outlines regenerative medicine path as investors weigh long-term growth - ad-hoc-news.de
Organogenesis Amnuvx Gets FDA Review for Knee OA - AllSci
FDA accepts Organogenesis’ application for knee osteoarthritis treatment - Investing.com
FDA accepts Organogenesis’ application for knee osteoarthritis treatment By Investing.com - Investing.com Nigeria
Organogenesis' Biologics License Application for ReNu Accepted by FDA for Review - Moomoo
FDA accepts Organogenesis' Biologics License Ap... - Pluang
Organogenesis Announces FDA Acceptance of Biologics License Application for ReNu® for the Management of Symptomatic Knee Osteoarthritis - The Manila Times
Organogenesis wins FDA review for ReNu, a knee osteoarthritis treatment - Stock Titan
ORGO Q1 2026 Earnings: EPS Misses Estimates Amidst Operational ChallengesCFO Commentary Report - dars.gov.et
ORGO Q1 2026 Earnings: EPS Misses Estimates by Wide Margin, Stock DeclinesUpward Estimate Revision - dars.gov.et
Enterprise value to revenue forward of Organogenesis Holdings Inc. – NASDAQ:ORGO - TradingView
Price to book forward of Organogenesis Holdings Inc. – NASDAQ:ORGO - TradingView
Price to sales forward of Organogenesis Holdings Inc. – NASDAQ:ORGO - TradingView
Organogenesis | 10-K: FY2025 Annual Report - Moomoo
Enterprise value to EBITDA forward of Organogenesis Holdings Inc. – NASDAQ:ORGO - TradingView
Price to earnings forward of Organogenesis Holdings Inc. – NASDAQ:ORGO - TradingView
Organogenesis Holdings Inc.(NasdaqCM:ORGO) dropped from Russell Small Cap Comp Growth Benchmark - marketscreener.com
Price to earnings forward of Organogenesis Holdings, Inc. Class A – LSX:A2PA31 - TradingView
Organogenesis Holdings Inc.(NasdaqCM:ORGO) dropped from Russell 2500 Growth Benchmark - marketscreener.com
Finanzdaten der Organogenesis Holdings Inc-Aktie (ORGO)
Umsatz
Nettogewinn
Free Cashflow
ENV
Organogenesis Holdings Inc-Aktie (ORGO) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Driscoll Michael Joseph | Director |
Mar 09 '26 |
Buy |
2.67 |
10,000 |
26,688 |
225,707 |
| NUSSDORF GLENN H | Director |
Dec 16 '25 |
Sale |
5.14 |
200,000 |
1,027,060 |
2,565,591 |
1.65%
8.60%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):